Impax Laboratories, Inc. (NASDAQ:IPXL) has been assigned a consensus rating of “Hold” from the eighteen ratings firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $19.04.

A number of research analysts have recently issued reports on the stock. Piper Jaffray Companies upgraded shares of Impax Laboratories from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $9.00 to $16.00 in a research note on Tuesday, July 18th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $10.00 price target on shares of Impax Laboratories in a research note on Sunday, April 2nd. Deutsche Bank AG set a $21.00 price target on shares of Impax Laboratories and gave the stock a “buy” rating in a research note on Monday, July 17th. BidaskClub upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Zacks Investment Research lowered shares of Impax Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 17th.

Impax Laboratories (NASDAQ:IPXL) traded up 3.08% during midday trading on Friday, hitting $20.10. 620,392 shares of the stock traded hands. Impax Laboratories has a one year low of $7.75 and a one year high of $31.85. The company’s market cap is $1.44 billion. The company’s 50 day moving average is $16.66 and its 200-day moving average is $13.97.

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by $0.01. Impax Laboratories had a positive return on equity of 7.71% and a negative net margin of 71.50%. The firm had revenue of $184.40 million for the quarter, compared to analyst estimates of $193.17 million. During the same quarter last year, the firm earned $0.43 earnings per share. The company’s revenue was down 18.2% compared to the same quarter last year. On average, equities research analysts forecast that Impax Laboratories will post $0.66 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Impax Laboratories, Inc. (NASDAQ:IPXL) Receives Average Recommendation of “Hold” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/28/impax-laboratories-inc-nasdaqipxl-receives-average-recommendation-of-hold-from-analysts.html.

Several hedge funds have recently made changes to their positions in the stock. Great West Life Assurance Co. Can increased its stake in shares of Impax Laboratories by 3.2% in the second quarter. Great West Life Assurance Co. Can now owns 106,856 shares of the specialty pharmaceutical company’s stock valued at $1,715,000 after buying an additional 3,350 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in shares of Impax Laboratories by 3.1% in the second quarter. Municipal Employees Retirement System of Michigan now owns 17,410 shares of the specialty pharmaceutical company’s stock valued at $280,000 after buying an additional 530 shares during the period. Legato Capital Management LLC increased its stake in shares of Impax Laboratories by 891.4% in the second quarter. Legato Capital Management LLC now owns 23,426 shares of the specialty pharmaceutical company’s stock valued at $377,000 after buying an additional 21,063 shares during the period. Aperio Group LLC increased its stake in shares of Impax Laboratories by 91.2% in the second quarter. Aperio Group LLC now owns 55,286 shares of the specialty pharmaceutical company’s stock valued at $890,000 after buying an additional 26,366 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in shares of Impax Laboratories by 78.7% in the second quarter. State of Alaska Department of Revenue now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $234,000 after buying an additional 6,408 shares during the period. 83.84% of the stock is currently owned by institutional investors.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.